Extract
We thank Hajime Fujimoto and co-workers for providing commentary on our article describing the prevalence and characteristics of progressive fibrosing interstitial lung disease (PF-ILD) [1]. We agree that highlighting individual predictors of progression by specific ILD subtype would help further refine risk stratification and guide management decisions.
Abstract
In a Canadian population with fibrotic hypersensitivity pneumonitis, only the presence of an identified antigen is associated with lower risk of progressive fibrosing interstitial lung diseasehttps://bit.ly/3FAcSqB
Footnotes
Author contributions: All authors contributed to the conception and design, acquisition of data, analyses and interpretation of the data, drafted the article, revised it critically for important intellectual content, and gave final approval of the version to be published.
Conflict of interest: M.M. Farooqi has nothing to disclose. N. Hambly reports grants from Boehringer Ingelheim and Janssen, and travel support and lecture honoraria from Boehringer Ingelheim, Janssen and Roche, outside the submitted work. C.J. Ryerson reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, consulting fees from Boehringer Ingelheim, Pliant Therapeutics and Veracyte, lecture honoraria from Hoffmann-La Roche, Boehringer Ingelheim and Cipla, and travel support from Cipla and Boehringer Ingelheim, outside the submitted work. M. Kolb reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, Pieris and Roche, consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Belerophon, Algernon and CSL Behring, lecture honoraria from Novartis, Boehringer Ingelheim and Roche, payment for expert testimony from Roche, advisory board participation with Covance and United Therapeutics, and reports a chief editor allowance from European Respiratory Society, outside the submitted work.
- ReceivedDecember 9, 2022.
- AcceptedDecember 12, 2022.
- Copyright ©The authors 2023. For reproduction rights and permissions contactpermissions{at}ersnet.org